In view of the caveats of VEGF treatment, the recently introduced engineered Wnt7a (eWnt7a) with potent and selective activation of Reck/Gpr124 may be better therapeutics to enhance post-stroke collateral circulation, because Wnt7a-activation simultaneously induces angiogenesis and the maturation of BBB (47, 48). The gene discussed is WNT7A; the disease is stroke disorder.